A poster by Biocytogen
Chaoshe Guo, Benny Yang, Huizhen Zhao, Yabo Zhang, Lili Liu, Hui Lu, Shuwen Huang, Yuelei Shen, Biocytogen
With the development of immune-oncology, therapeutic antibodies have been proven to be extraordinarily effective for cancer treatment.
Conventional human antibody discovery process can be divided into steps including target selection, target validation, screening preparation, hits generation, leads selection, lead optimization, and clinical candidate selection.
To accelerate antibody development process, Biocytogen has developed RenMab™ Mouse, a fully human antibody mouse whose entire variable regions were replaced by human Ig heavy chain and κ light chain through Biocytogen's unique Mb-scale chromosome engineering technology.
RenMab™ Mouse provides a remarkably efficient therapeutic antibody discovery platform for fully human antibody generation, characterization, and rapid in vivo efficacy screening.
We have characterized RenMab™ Mouse with the following features.
In conclusion, RenMab™ Mouse, a fully human antibody mouse developed by Biocytogen’s chromosome engineering technology, has been proven to exhibit normal immune cell profile and rapid immune response.
Combined with existing inventory of single, double or triple target humanized mouse models and a world-leading proprietary gene editing platform, Biocytogen is dedicated to providing a one-stop solution for antibody discovery and development from target validation to IND application.